General Information of Drug (ID: DMREZ9I)

Drug Name
PMID28270021-Compound-WO2016054807Example71 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic pain MG30 Patented [1]
Neuropathic pain 8E43.0 Patented [1]
Pruritus EC90 Patented [1]
Solid tumour/cancer 2A00-2F9Z Patented [1]
Thymic cancer 2C27 Patented [1]
Cross-matching ID
TTD Drug ID
DMREZ9I

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [3]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [4]
MIM-D3 DMZHN5B Alzheimer disease 8A20 Phase 3 [5]
SNA-120 DMPN314 Plaque psoriasis EA90.0 Phase 2 [6]
CT 327 DMQXL1T Plaque psoriasis EA90.0 Phase 2 [7]
ONO-7579 DMXLPYE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Altiratinib DMUJCBT Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [9]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [1]

References

1 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
8 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
9 National Cancer Institute Drug Dictionary (drug id 747694).
10 National Cancer Institute Drug Dictionary (drug id 766123).